Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is a top-performing large cap stock. New data from the HELIOS-B Phase 3 study of its RNAi therapeutic, AMVUTTRA (vutrisiran), showed a 42% lower rate of GI events in patients with transthyretin-mediated amyloidosis. Symptoms like diarrhea, nausea, and vomiting reduced by over 50%.

Vutrisiran, an RNAi therapeutic by Alnylam, shows promising results in reducing GI events in patients with ATTR-CM. This treatment led to reductions in symptoms like diarrhea, nausea, and vomiting by over 50% across different patient groups. The study demonstrates the efficacy of vutrisiran in managing these symptoms effectively and rapidly.

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) focuses on developing therapeutics based on ribonucleic acid interference. The company is recognized for its innovative approach to treating various diseases using RNAi technology. Investors interested in the biotech sector may find opportunities in ALNY and other AI stocks with growth potential.

For investors considering AI stocks, ALNY presents investment potential. However, other AI stocks may offer greater upside and lower downside risks. Investors seeking undervalued AI stocks can explore opportunities beyond ALNY. Understanding market trends and potential growth areas is crucial for making informed investment decisions.

Read more at Yahoo Finance: Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data